POST-4
2021
Prevention of Syncope Trial 4
In 133 patients with recurrent vasovagal syncope and no serious comorbidity, midodrine reduced the proportion of patients with at least one syncope episode over 12 months compared with placebo.
Result
Efficacy: Proportion with ≥1 syncope episode over 12 monthsrelative risk 0.69 (95% CI 0.49-0.97) · P = 0.035
Below 1 favours midodrine, above 1 favours placebo.
- Absolute difference
- 19 points
- NNT
- 6
Absolute difference and NNT are derived from the event rates.
Also reported: Absolute reduction 19 percentage points; NNT 5.3. Adverse effects similar in both arms.
- Subtopic
- Vasovagal syncope
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Source
- Sheldon R, Faris P, Tang A, et al. Ann Intern Med. 2021;174(10):1349-1356.doi 10.7326/M20-5415
Discussion & critique
Small, short of its planned enrolment, followed for only 12 months and drawn largely from one centre, so the confidence interval brushes unity. Even so it is the only adequately powered placebo-controlled trial of midodrine and makes it the best-supported drug for young, healthy patients with a heavy syncope burden.